• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

VentiRx Pharmaceuticals

edit

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel toll-like receptor 8 therapeutics for the treatment of cancer, respiratory, allergy, and autoimmune/inflammatory diseases. The company was founded in 2006 and is headquartered in San Diego, California with additional operations in Seattle.

Recent Milestones

edit

• 
  VentiRx Pharmaceuticals received $35M in Venture Round funding. (10/3/12)
  Posted 10/3/12 at 6:49pm via dowjones.com
• 
  VentiRx Pharmaceuticals received $51.6M in Series A funding. (1/13/10)
  Posted 1/12/10 at 7:21pm via dowjones.com
• 
  VentiRx Pharmaceuticals added Michael J. Kamdar as Co-Founder .
  Posted 1/12/10 at 7:21pm
• 
  VentiRx Pharmaceuticals added Robert M. Hershberg as Co-Founder .
  Posted 1/12/10 at 7:21pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/13/10

Sources

1. VentiRx Pharma Extends Series A To $51.6M (fis.dowjones.com) [edit]
2. VentiRx Secures $35M from Celgene; VCs Get Possible Path to Liquidity (pevc.dowjones.com) [edit]